We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · March 02, 2021

Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell RCC

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
J. Clin. Oncol 2021 Feb 02;[EPub Ahead of Print], DF McDermott, JL Lee, M Ziobro, C Suarez, P Langiewicz, VB Matveev, P Wiechno, RA Gafanov, P Tomczak, F Pouliot, F Donskov, BY Alekseev, SJ Shin, GA Bjarnason, D Castellano, RK Silverman, RF Perini, C Schloss, MB Atkins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading